QRxPharma seeks second review at FDA for pain drug MoxDuo
This article was originally published in Scrip
Executive Summary
Shares of QRxPharma got a 3% boost on 28 February when the company said it had resubmitted its new drug application (NDA) to the US FDA for MoxDuo as a treatment for moderate to severe acute pain.